270912-79-3 Usage
Uses
Used in Pharmaceutical Industry:
(5-BROMO-PYRIMIDIN-2-YLOXY)-ACETIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential to contribute to the development of new medicines.
Used in Agrochemical Industry:
(5-BROMO-PYRIMIDIN-2-YLOXY)-ACETIC ACID is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its ability to enhance the effectiveness of these products.
Used in Organic Synthesis:
(5-BROMO-PYRIMIDIN-2-YLOXY)-ACETIC ACID is used as a building block in organic synthesis for its versatility in forming various chemical structures, contributing to the creation of a wide range of compounds.
Used in Chemical Research:
(5-BROMO-PYRIMIDIN-2-YLOXY)-ACETIC ACID is used as a research compound in the chemical industry to explore its properties and potential applications, furthering the understanding of pyrimidine derivatives and their role in various chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 270912-79-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,0,9,1 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 270912-79:
(8*2)+(7*7)+(6*0)+(5*9)+(4*1)+(3*2)+(2*7)+(1*9)=143
143 % 10 = 3
So 270912-79-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H5BrN2O3/c7-4-1-8-6(9-2-4)12-3-5(10)11/h1-2H,3H2,(H,10,11)
270912-79-3Relevant academic research and scientific papers
2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists
-
Page/Page column 24; 30-31, (2010/02/05)
This invention relates to certain pyrimidine derivatives that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
Pyrrolidine derivatives-CCR-3 receptor antagonists
-
, (2008/06/13)
This invention relates to certain 3-aminomethylpyrrolidine derivatives of Formula (I): that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
